Should the presence of germline BRCA1/2 mutations influence treatment selection in breast cancer?
- PMID: 21900108
- DOI: 10.1200/JCO.2011.37.2540
Should the presence of germline BRCA1/2 mutations influence treatment selection in breast cancer?
Comment on
-
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.J Clin Oncol. 2011 Oct 1;29(28):3739-46. doi: 10.1200/JCO.2011.35.2682. Epub 2011 Sep 6. J Clin Oncol. 2011. PMID: 21900106 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
